| Revision as of 18:05, 29 July 2010 editPotatoBot (talk | contribs)Bots51,239 editsm Stub sorting and placement of stub template(s)← Previous edit |
Latest revision as of 14:23, 26 September 2023 edit undoEntranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers172,083 edits Importing Wikidata short description: "Pharmaceutical drug"Tag: Shortdesc helper |
| (36 intermediate revisions by 23 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Pharmaceutical drug}} |
|
{{Unreferenced stub|auto=yes|date=December 2009}} |
|
|
{{Drugbox |
|
{{Drugbox |
|
|
| Verifiedfields = changed |
|
| IUPAC_name = |
|
|
|
| Watchedfields = changed |
| ⚫ |
| image = Tyloxapol.png |
|
|
|
| verifiedrevid = 376126506 |
| ⚫ |
| width = 150 |
|
|
|
| IUPAC_name = formaldehyde;oxirane;4-(2,4,4-trimethylpentan-2-yl)phenol |
| ⚫ |
| CAS_number = 25301-02-4 |
|
|
⚫ |
| image = Tyloxapol.png |
| ⚫ |
| ATC_prefix = R05 |
|
|
⚫ |
| width = 150 |
| ⚫ |
| ATC_suffix = CA01 |
|
|
|
|
| ⚫ |
| PubChem = 71388 |
|
|
|
<!--Clinical data--> |
| ⚫ |
| DrugBank = |
|
|
|
| tradename = |
| ⚫ |
| chemical_formula = (C<sub>15</sub>H<sub>21</sub>O(C<sub>2</sub>H<sub>4</sub>O)<sub>m</sub>)<sub>n</sub> |
|
|
|
| Drugs.com = {{drugs.com|international|tyloxapol}} |
| ⚫ |
| molecular_weight = variable |
|
|
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
| ⚫ |
| bioavailability = |
|
|
⚫ |
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| protein_bound = |
|
|
|
| pregnancy_category = |
| ⚫ |
| metabolism = |
|
|
⚫ |
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
| ⚫ |
| elimination_half-life = |
|
|
⚫ |
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
| ⚫ |
| excretion = |
|
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
| pregnancy_category= |
|
| legal_status = |
|
⚫ |
| routes_of_administration = |
| ⚫ |
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
|
|
|
| ⚫ |
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
|
|
<!--Pharmacokinetic data--> |
| ⚫ |
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
|
⚫ |
| bioavailability = |
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
|
| legal_status = |
|
| protein_bound = |
|
⚫ |
| metabolism = |
| ⚫ |
| routes_of_administration = |
|
|
⚫ |
| elimination_half-life = |
|
⚫ |
| excretion = |
|
|
|
|
|
<!--Identifiers--> |
|
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
⚫ |
| CAS_number = 25301-02-4 |
|
⚫ |
| ATC_prefix = R05 |
|
⚫ |
| ATC_suffix = CA01 |
|
⚫ |
| PubChem = 71388 |
|
|
| DrugBank_Ref = {{drugbankcite|changed|drugbank}} |
|
⚫ |
| DrugBank = DB06439 |
|
|
| ChemSpiderID = None |
|
|
| UNII_Ref = {{fdacite|changed|FDA}} |
|
|
| UNII = Y27PUL9H56 |
|
|
| KEGG_Ref = {{keggcite|changed|kegg}} |
|
|
| KEGG = D03261 |
|
|
| ChEBI = 141517 |
|
|
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
|
|
| ChEMBL = 1201548 |
|
|
|
|
|
<!--Chemical data--> |
|
⚫ |
| chemical_formula = (C<sub>15</sub>H<sub>21</sub>O(C<sub>2</sub>H<sub>4</sub>O)<sub>m</sub>)<sub>n</sub> |
|
⚫ |
| molecular_weight = variable |
|
}} |
|
}} |
|
|
|
|
|
'''Tyloxapol''' is a nonionic liquid ] of the alkyl aryl polyether alcohol type. It is used as a ] to aid ] and removal of mucopurulent (containing ] and ]) bronchopulmonary secretions, administered by inhalation through a ] or with a stream of oxygen. |
|
'''Tyloxapol''' is a nonionic liquid ] of the alkyl aryl polyether alcohol type. It is used as a ] to aid ] and removal of mucopurulent{{citation needed|date=December 2013}} (containing ] and ]) bronchopulmonary secretions,<ref>{{cite journal | vauthors = Sehgal SS, Ewing CK, Richards T, Taeusch HW | title = Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study | journal = Journal of the National Medical Association | volume = 86 | issue = 1 | pages = 46–52 | date = January 1994 | pmid = 8151722 | pmc = 2607653 }}</ref><ref>{{cite journal | vauthors = Rubin BK, Ramirez O, King M | title = Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy | journal = Chest | volume = 101 | issue = 4 | pages = 1080–5 | date = April 1992 | pmid = 1555424 | doi = 10.1378/chest.101.4.1080 }}</ref> administered by inhalation through a ]<ref>{{cite web | work = Drugs.com | url = https://www.drugs.com/dict/tyloxapol.html | title = Tyloxapol definition }}</ref> or with a stream of oxygen. |
|
|
|
|
With ], tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of ]-rich ]s. |
|
|
|
With ], tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of ]-rich ]s. This mechanism is used to induce experimental ] in animals.<ref>{{cite journal | vauthors = Kourounakis AP, Victoratos P, Peroulis N, Stefanou N, Yiangou M, Hadjipetrou L, Kourounakis PN | title = Experimental hyperlipidemia and the effect of NSAIDs | journal = Experimental and Molecular Pathology | volume = 73 | issue = 2 | pages = 135–8 | date = October 2002 | pmid = 12231215 | doi = 10.1006/exmp.2002.2449 }}</ref> |
|
|
|
|
|
Tyloxapol is the main active ingredient of the medical device Tacholiquin. Tacholiquin is an expectorant designated for inhalation and instillation reaching the upper and lower airways. |
|
|
Other brand names of pharmaceutical products containing Tyloxapol are Exosurf and Alevaire. |
|
|
|
|
|
== References == |
|
|
{{reflist}} |
|
|
|
|
|
{{Cough and cold preparations}} |
|
{{Cough and cold preparations}} |
|
|
|
|
|
] |
|
] |
|
|
] |
|
|
|
|
|
|
|
|
{{respiratory-system-drug-stub}} |
|
{{respiratory-system-drug-stub}} |
|
|
|
|
] |
|